![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/launching-its-epinephrine-nasal-spray-ars-pharma-has-blue-sky-opportunity-leerink-says
https://www.indianpharmapost.com/news/aptars-nasal-unidose-system-delivers-fda-approved-neffy-16052
https://www.prnewswire.com/news-releases/fda-approves-first-nasal-spray-for-treatment-of-anaphylaxis-302218924.html
https://www.globenewswire.com/news-release/2024/08/06/2925519/0/en/Aquestive-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.prnewswire.com/news-releases/nasus-pharma-announces-ground-breaking-five-years-stability-of-its-fmxin002-nasal-epinephrine-powder-for-severe-allergy-and-anaphylaxis-302215369.html
https://www.globenewswire.com/news-release/2024/08/06/2925406/0/en/ARS-Pharmaceuticals-Provides-Business-Highlights-and-Reports-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/07/25/2918762/0/en/Aquestive-Therapeutics-Reports-Positive-Topline-Data-for-Anaphylm-epinephrine-Sublingual-Film-from-Self-Administration-Study.html
https://www.contractpharma.com/contents/view_breaking-news/2024-07-24/de-motu-cordis-expands-dpi-partnership-with-catalent/?widget=listSection
https://www.prnewswire.com/news-releases/de-motu-cordis-dmc-announces-plans-for-the-next-stage-of-development-for-dmc-ih1-an-inhaled-epinephrine-drug-device-combination-product-302198919.html
https://www.globenewswire.com/news-release/2024/06/25/2903743/0/en/Aquestive-Therapeutics-Reports-Positive-Topline-Data-from-Temperature-pH-Study-of-Anaphylm-epinephrine-Sublingual-Film.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-5-2024-58484.pdf
https://www.globenewswire.com/news-release/2024/05/28/2888980/0/en/Aquestive-Therapeutics-to-Present-Anaphylm-epinephrine-Sublingual-Film-Pharmacokinetic-and-Pharmacodynamic-Data-At-2024-Eastern-Allergy-Conference.html
https://www.globenewswire.com/news-release/2024/05/09/2879194/0/en/ARS-Pharmaceuticals-Highlights-neffy-Regulatory-Progress-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/07/2877273/0/en/Aquestive-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/30/2872354/0/en/ARS-Pharmaceuticals-Submits-Response-for-neffy-epinephrine-nasal-spray-Marketing-Authorization-Application-to-EMA-s-CHMP-and-Enters-License-Agreement-with-CSL-Seqirus-for-Commercia.html
https://www.indianpharmapost.com/news/orexo-extends-patent-protection-for-its-nasal-epinephrine-powder-product-ox640-in-the-us-15552
https://www.prnewswire.com/news-releases/orexo-extends-patent-protection-for-its-nasal-epinephrine-powder-product-ox640-in-the-us-302119102.html
https://endpts.com/endo-sues-fda-over-its-handling-of-generic-adrenalin-approvals/
https://www.globenewswire.com/news-release/2024/04/03/2857016/0/en/ARS-Pharmaceuticals-Submits-Response-to-FDA-Complete-Response-Letter-for-neffy-Epinephrine-Nasal-Spray.html
https://www.transopharm.com/blog/transo-pharm-guarantees-uninterrupted-epinephrine-supply
https://www.pharmaceutical-technology.com/news/ars-gears-up-for-neffy-us-approval/
https://www.globenewswire.com//news-release/2024/03/14/2846751/0/en/Aquestive-Therapeutics-Announces-Pivotal-Study-for-Anaphylm-epinephrine-Sublingual-Film-Successfully-Meets-Primary-and-Secondary-Endpoints-and-Provides-Clinical-Development-Update-.html
https://www.globenewswire.com//news-release/2024/03/07/2842745/0/en/ARS-Pharmaceuticals-Reviews-Recent-Clinical-Updates-and-Commercial-Opportunity-at-neffy-Investor-Day.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-28-2024-59068.pdf
https://www.globenewswire.com//news-release/2024/02/20/2831938/0/en/ARS-Pharma-Announces-Favorable-Topline-Results-from-Repeat-Dosing-Study-of-neffy-Epinephrine-Nasal-Spray-Under-Nasal-Allergen-Challenge-Conditions-Readies-Data-for-Response-to-FDA-.html
https://www.globenewswire.com//news-release/2024/02/15/2829938/0/en/Aquestive-Therapeutics-to-Present-Anaphylm-epinephrine-Sublingual-Film-Pharmacokinetic-and-Pharmacodynamic-Data-at-the-2024-AAAAI-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/05/2823584/0/en/ARS-Pharmaceuticals-to-Present-Positive-Clinical-Efficacy-Data-for-neffy-epinephrine-nasal-spray-at-2024-AAAAI-Annual-Meeting.html
https://www.prnewswire.com/news-releases/positive-results-from-pivotal-study-for-bryn-pharmas-investigational-epinephrine-nasal-spray-published-in-the-journal-of-allergy-and-clinical-immunology-global-302012899.html
https://www.globenewswire.com/news-release/2023/12/05/2790868/0/en/Aquestive-Therapeutics-Doses-First-Patient-in-Phase-3-Pivotal-Clinical-Study-Evaluating-Pharmacokinetics-and-Pharmacodynamics-of-Anaphylm-epinephrine-Sublingual-Film.html
https://www.globenewswire.com//news-release/2023/11/09/2777587/0/en/ARS-Pharmaceuticals-Announces-Presentation-of-Clinical-Data-Supporting-neffy-epinephrine-nasal-spray-for-the-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-11-2023-46012.pdf
https://www.globenewswire.com//news-release/2023/10/06/2756120/0/en/ARS-Pharmaceuticals-Announces-Scheduling-of-a-Type-A-Meeting-with-the-U-S-FDA-for-neffy-epinephrine-nasal-spray.html
https://www.globenewswire.com//news-release/2023/10/03/2753749/0/en/Single-and-Repeat-Dose-Clinical-Study-of-neffy-epinephrine-nasal-spray-Published-in-the-Journal-of-Allergy-and-Clinical-Immunology.html
https://www.globenewswire.com/news-release/2023/09/20/2746095/0/en/FDA-Issues-Complete-Response-Letter-for-neffy-epinephrine-nasal-spray-New-Drug-Application-with-Request-for-Additional-Study.html
https://www.globenewswire.com//news-release/2023/09/20/2746543/0/en/Aquestive-Therapeutics-Reaffirms-Timeline-and-Pathway-for-Anaphylm-epinephrine-Sublingual-Film.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-6-2023-36272.pdf
https://www.prnewswire.com/news-releases/orexo-secures-patent-protection-in-the-us-for-ox640-a-nasal-epinephrine-powder-product-301912063.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-9-2023-9584.pdf
https://www.globenewswire.com/news-release/2023/07/27/2712029/0/en/Aquestive-Therapeutics-Announces-Positive-Topline-Pharmacokinetic-Data-for-Anaphylm-epinephrine-Sublingual-Film.html
https://endpts.com/chinas-market-regulator-fines-two-pharmas-confiscates-revenue-for-monopolizing-apis/
https://www.globenewswire.com/news-release/2023/05/31/2679318/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Latest-Clinical-Studies-Evaluating-Pharmacokinetic-and-Pharmacodynamic-Performance-of-Anaphylm-epinephrine-Sublingual-Film-and-.html
https://recalls-rappels.canada.ca/en/alert-recall/bausch-health-canada-inc-recalls-all-lots-emerade-epinephrine-auto-injectors-03-mg-and
https://www.globenewswire.com/news-release/2023/04/20/2650942/0/en/Aquestive-Therapeutics-Receives-Conditional-FDA-Acceptance-of-Proprietary-Name-Anaphylm-for-Lead-Candidate-AQST-109-Epinephrine-Sublingual-Film.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2023-50304.pdf
https://www.prnewswire.com/news-releases/american-regent-introduces-fda-approved-epinephrine-injection-usp-301785877.html
https://www.globenewswire.com/news-release/2023/02/23/2614776/0/en/ARS-Pharmaceuticals-Announces-Presentation-of-Data-Supporting-neffy-epinephrine-nasal-spray-and-Real-World-Burden-of-Needle-Injectors.html
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11202310416
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-25-2023-68767.pdf